- THRBF offers an IoT- and Bluetooth-enabled device for cold-sore prevention
- Its sales strategy is part of the company’s larger focus on developing products for the dermatology market
- THRBF’s proprietary technology is designed to prevent cold sores in the OTC sector, which is projected to record significant sales growth
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is offering a new generation of technology in the burgeoning skin care market. The company is specifically planning to target sales growth for its high gross-margin InterceptCS* cold sore prevention device with a new website, social media campaign and online sales strategy (http://cnw.fm/7Ahvq).
THRBF’s new InterceptCS is a class II medical device that works through three 30-second treatments and offers multi-use activators. Therma Bright’s strategy is to market the product online through distributors and a new social media campaign, as well as on its new website at www.ColdSores.com.
Toronto-based THRBF offers first-rate medical devices for dermatological needs. The company focuses on proprietary technology in the OTC pain-free and noninvasive sectors, and it has received class II medical device status from the U.S. Food and Drug Administration (FDA). Therma Bright also markets TherOZap, an insect-bite treatment device.
The dermatology market is estimated to reach $22.6 billion in the United States by 2028, according to GMR Data (http://cnw.fm/7kvXq).
* Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome,” by Health Canada. InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficac, and/or cure or prevention of disease.
For more information, visit the company’s website at www.ThermaBright.com
NOTE TO INVESTORS: The latest news and updates relating to THRBF are available in the company’s newsroom at http://cnw.fm/THRBF
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Receive Text Alerts from CBDWire: Text “Cannabis” to 21000
For more information please visit https://www.cbdwire.com and or https://CBDWire.News
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
